Ratings OSE Immunotherapeutics

Equities

OSE

FR0012127173

Market Closed - Euronext Paris Other stock markets 11:35:09 2024-04-25 am EDT			5-day change	1st Jan Change
5.6 ^EUR	-0.71%		+12.00%	+30.84%

Apr. 17	OSE: licensing agreement with AbbVie enters into force	CF
Apr. 17	OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
OSE IMMUNOTHERAPEUTICS	+30.84%	130M	D
IQVIA HOLDINGS INC.	+1.12%	43.84B	B
MODERNA, INC.	+6.77%	41.68B	B-
LONZA GROUP AG	+45.26%	41.25B	A
CELLTRION, INC.	-11.96%	27.04B	C
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B	B-
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B	B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B	C+
MEDPACE HOLDINGS, INC.	+27.16%	12.29B	C+
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes